Literature DB >> 15772297

New fACEs to the renin-angiotensin system.

Ingrid Fleming1, Karin Kohlstedt, Rudi Busse.   

Abstract

Inhibition of the angiotensin-converting enzyme (ACE) protects against the progression of several cardiovascular diseases. Recent evidence suggests that some of the beneficial effects of ACE inhibitors can be attributed to the activation of a distinct ACE signaling cascade rather than to the changes in angiotensin II and bradykinin levels. Moreover, at least one other ACE homolog (ACE2) plays a significant role in the regulation of heart and kidney function.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15772297     DOI： 10.1152/physiol.00003.2005

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN： 1548-9221


  9 in total

Review 1.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

Review 2.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

Review 3.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

4.  ACE as a mechanosensor to shear stress influences the control of its own regulation via phosphorylation of cytoplasmic Ser(1270).

Authors:  Valerio Garrone Barauna; Luciene Cristina Gastalho Campos; Ayumi Aurea Miyakawa; Jose Eduardo Krieger
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

Review 5.  ACE-I/ARB therapy prior to contrast exposure: what should the clinician do?

Authors:  Robert Kalyesubula; Peace Bagasha; Mark A Perazella
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

Review 6.  Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.

Authors:  Maira Soto; Gere diZerega; Kathleen E Rodgers
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636

7.  Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes.

Authors:  Michael L Merchant; Monika A Niewczas; Linda H Ficociello; Janice A Lukenbill; Daniel W Wilkey; Ming Li; Syed J Khundmiri; James H Warram; Andrzej S Krolewski; Jon B Klein
Journal:  Kidney Int       Date:  2013-03-06       Impact factor: 10.612

Review 8.  Widening and Elaboration of Consecutive Research into Therapeutic Antioxidant Enzyme Derivatives.

Authors:  Alexander V Maksimenko
Journal:  Oxid Med Cell Longev       Date:  2016-04-11       Impact factor: 6.543

9.  Renin-angiotensin-aldosterone system blockade is associated with higher risk of contrast-induced acute kidney injury in patients with diabetes.

Authors:  Mengqing Ma; Xin Wan; Min Gao; Binbin Pan; Dawei Chen; Qing Sun; Mengyu Zhang; Changgao Zhou; Tao Li; Hanchao Pan; Wei Shao; Zhihe Liu; Yue Chen; Changchun Cao
Journal:  Aging (Albany NY)       Date:  2020-04-02       Impact factor: 5.682
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.